Genentech, Inc.

Genentech, Inc. specializes in ophthalmic medical devices, including single-use ophthalmic needles for precise eye injections, implantable intraocular medication reservoirs for controlled drug delivery, and single-use ophthalmic implant handling forceps. These devices are designed to support treatments for eye conditions like chronic inflammation or infection, ensuring targeted and sustained therapeutic effects.

Genentech, Inc. is based in the United States, which means its devices are subject to FDA regulations. The company’s products are classified under FDA’s Class I, Class II, and non-classifiable (N) categories, reflecting varying levels of risk and regulatory oversight. Being US-based also ensures compliance with domestic standards while potentially facilitating international market access through FDA’s regulatory pathways.

Genentech’s devices are listed in the FDA’s Unique Device Identifier (UDI) database. This registry ensures traceability, transparency, and compliance with regulatory requirements by assigning a standardized identifier to each device, helping track products throughout their lifecycle and supporting post-market surveillance efforts.

Genentech’s devices fall under different FDA classifications: Class I (generally low-risk devices requiring minimal regulation), Class II (devices with moderate risk requiring special controls), and non-classifiable (N) for those that don’t fit standard classifications. The classification depends on factors like the device’s purpose, potential risks, and intended use in eye treatments, ensuring appropriate regulatory oversight.